114940-132

A randomized, double-blind, placebo (Pbo)-controlled phase III study of ombrabulin plus cisplatin in patients (pts) with advanced-stage soft-tissue sarcoma after failure of anthracycline and ifosfamide chemotherapies.

Subcategory: 
Category: 
Sarcoma
Session Type and Session Title: 
Oral Abstract Session, Sarcoma
Abstract Number: 

10506

Citation: 

J Clin Oncol 31, 2013 (suppl; abstr 10506)

Author(s): 

Zsuzsanna Papai, Anthony W. Tolcher, Antoine Italiano, Didier Cupissol, Antonio Lopez-Pousa, Sant P. Chawla, Emmanuelle Bompas, Nicolas Penel, Nicolas Isambert, Arthur P. Staddon, Antoine Thyss, Armando Santoro, Fabio A. Franke, Patrick Cohen, Solenn Le-Guennec, George D. Demetri, Jean-Yves Blay; Állami Egészségügyi Központ, Budapest, Hungary; South Texas Accelerated Research Therapeutics (START), San Antonio, TX; Institut Bergonié, Bordeaux, France; Centre Val d’Aurelle, Montpellier, France; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; St. John's Hospital, Santa Monica, CA; Centre René Gauducheau, Nantes, France; Centre Oscar Lambret, Lille, France; Centre Georges François Leclerc, Dijon, France; Pennsylvania Oncology Hematology Associates, Philadelphia, PA; Centre Antoine Lacassagne, Nice, France; Istituto Clinico Humanitas IRCCS, Milano, Italy; CACON-Hospital de Caridade de Ijui, Ijui, Brazil; Sanofi, Vitry-sur-Seine, France; Ludwig Center at Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Centre Léon Bérard, Lyon, France


Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).

Abstract Disclosures

Abstract: 

Background: Ombrabulin (AVE8062) is a vascular disrupting agent that damages established tumor vasculature and has demonstrated synergistic antitumor activity with cisplatin in vivo. In a phase I study, ombrabulin 25 mg/m² plus cisplatin 75 mg/m² was identified as the recommended dose in pts with solid tumors (AACR 2008; Abs 08-AB-4925). This phase III study evaluated the efficacy and safety of ombrabulin plus cisplatin in pts with advanced soft-tissue sarcoma (NCT00699517). Methods: Pts (aged ≥18 yrs, ECOG PS ≤2) with metastatic soft-tissue sarcoma who had received prior anthracycline and ifosfamide, with ≤2 prior chemotherapies for advanced disease, were randomized (1:1) to receive either ombrabulin 25 mg/m² or Pbo plus cisplatin 75 mg/m² every 3 weeks. The primary objective was to compare progression-free survival (PFS) between arms; secondary objectives included overall survival (OS) and safety. Results: Overall, 355 pts (median age 52 yrs; 51.5% male) were randomized (176 ombrabulin, 179 Pbo) in 44 centers worldwide. Median duration of follow-up was 27.9 and 30.5 months in Pbo and ombrabulin arms, respectively. PFS analysis showed a statistically significant improvement with ombrabulin (median 1.54 vs 1.41 months Pbo; HR=0.76, 95% CI 0.59–0.98; p=0.0302), with 3- and 6-month rates in favor of ombrabulin vs Pbo: 35.4% vs 24.9% and 19.3% vs 10.6%, respectively. A trend for an improvement with ombrabulin was observed in 3 of the 4 prespecified histology strata: liposarcoma, leiomyosarcoma, and “other”, but not for pleomorphic. Analysis of OS did not show statistically significant improvement with ombrabulin (median 11.43 vs 9.33 months Pbo, HR=0.85, 95% CI 0.67–1.09). OS rates at 1 year were in favor of ombrabulin (48.6% vs 42.4% Pbo). Grade 3/4 TEAEs more frequently seen with ombrabulin included neutropenia (19.2% vs 7.9% Pbo) and thrombocytopenia (8.5% vs 3.4% Pbo). Conclusions: Although this trial met its primary efficacy endpoint, the combination of ombrabulin and cisplatin did not demonstrate sufficient clinical benefit in pts with advanced soft-tissue sarcoma to warrant further study. Clinical trial information: NCT00699517.